The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Mechanisms by Which Low Glucose Enhances the Cytotoxicity of Metformin to Cancer Cells Both In Vitro and In Vivo
Open accessAbstract
Different cancer cells exhibit altered sensitivity to metformin treatment. Recent studies suggest these findings may be due in part to the common cell culture practice of utilizing high glucose, and when glucose is lowered, metformin becomes increasingly cytotoxic to cancer cells. In low glucose conditions ranging from 0 to 5 mM, metformin was cytotoxic to breast cancer cell lines MCF7, MDAMB231 and SKBR3, and ovarian cancer cell lines OVCAR3, and PA-1. MDAMB231 and SKBR3 were previously shown to be resistant to metformin in normal high glucose medium. When glucose was increased to 10 mM or above, all of these cell lines become less responsive to metformin treatment. Metformin treatment significantly reduced ATP levels in cells incubated in media with low glucose (2.5 mM), high fructose (25 mM) or galactose (25 mM). Reductions in ATP levels were not observed with high glucose (25 mM). This was compensated by enhanced glycolysis through activation of AMPK when oxidative phosphorylation was inhibited by metformin. However, enhanced glycolysis was either diminished or abolished by replacing 25 mM glucose with 2.5 mM glucose, 25 mM fructose or 25 mM galactose. These findings suggest that lowering glucose potentiates metformin induced cell death by reducing metformin stimulated glycolysis. Additionally, under low glucose conditions metformin significantly decreased phosphorylation of AKT and various targets of mTOR, while phospho-AMPK was not significantly altered. Thus inhibition of mTOR signaling appears to be independent of AMPK activation. Further in vivo studies using the 4T1 breast cancer mouse model confirmed that metformin inhibition of tumor growth was enhanced when serum glucose levels were reduced via low carbohydrate ketogenic diets. The data support a model in which metformin treatment of cancer cells in low glucose medium leads to cell death by decreasing ATP production and inhibition of survival signaling pathways. The enhanced cytotoxicity of metformin against cancer cells was observed both in vitro and in vivo.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“These results are consistent with previous studies reporting the synergism of the metformin/low glucose combination (Birsoy et al., 2014; Zhuang et al., 2014).”
From Combination of Hypoglycemia and Metformin Impairs Tumor Metabolic Plasticity and Growth by Modulating the PP2A-GSK3β-MCL-1 Axis (2019) · cites this paper as Zhuang et al., 2014
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011 · cited 1×
“Metformin’s potential anti-cancer activity was implicated by the lower incidence of cancer in type II diabetics versus other glucose controlling drugs [9].”
BackgroundMetformin and reduced risk of cancer in diabetic patients
Evans, J. M. M., Donnelly, L. A., Emslie-Smith, A. M., Alessi, D. R., & Morris, A. D. (2005) · BMJ · doi:10.1136/bmj.38415.708634.f7 · Cited by 2,388
OWEN, M. R., DORAN, E., & HALESTRAP, A. P. (2000) · Biochemical Journal · doi:10.1042/bj3480607 · Cited by 2,157
Metformin improves healthspan and lifespan in mice
Martin-Montalvo, A., Mercken, E. M., Mitchell, S. J., Palacios, H. H., Mote, P. L., Scheibye-Knudsen, M., Gomes, A. P., Ward, T. M., Minor, R. K., Blouin, M.-J., et al. (2013) · Nature Communications · doi:10.1038/ncomms3192 · Cited by 1,445
El-Mir, M.-Y., Nogueira, V., Fontaine, E., Avéret, N., Rigoulet, M., & Leverve, X. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.1.223 · Cited by 1,399
Efficacy of Metformin in Patients with Non-Insulin-Dependent Diabetes Mellitus
DeFronzo, R. A., & Goodman, A. M. (1995) · New England Journal of Medicine · doi:10.1056/nejm199508313330902 · Cited by 1,368
Evidence that glutamine, not sugar, is the major energy source for cultured HeLa cells.
Reitzer, L. J., Wice, B. M., & Kennell, D. (1979) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)30124-2 · Cited by 1,240
Aslakson, C. J., & Miller, F. R. (1992) · PubMed · Cited by 1,234
Hirsch, H. A., Iliopoulos, D., Tsichlis, P. N., & Struhl, K. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-2994 · Cited by 1,115
Buzzai, M., Jones, R. G., Amaravadi, R. K., Lum, J. J., DeBerardinis, R. J., Zhao, F., Viollet, B., & Thompson, C. B. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4447 · Cited by 949
Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus
Salpeter, S. R., Greyber, E., Pasternak, G. A., & Salpeter (posthumous), E. E. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002967.pub4 · Cited by 893
Marsin, A.-S., Bertrand, L., Rider, M. H., Deprez, J., Beauloye, C., Vincent, M. F., den Berghe, G. V., Carling, D., & Hue, L. (2000) · Current Biology · doi:10.1016/s0960-9822(00)00742-9 · Cited by 853
Marroquin, L. D., Hynes, J., Dykens, J. A., Jamieson, J. D., & Will, Y. (2007) · Toxicological Sciences · doi:10.1093/toxsci/kfm052 · Cited by 632
Shackelford, D. B., Abt, E., Gerken, L., Vasquez, D. S., Seki, A., Leblanc, M., Wei, L., Fishbein, M. C., Czernin, J., Mischel, P. S., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2012.12.008 · Cited by 585
Sahra, I. B., Laurent, K., Giuliano, S., Larbret, F., Ponzio, G., Gounon, P., MARCHAND‐BRUSTEL, Y. L., Giorgetti‐Peraldi, S., Cormont, M., Bertolotto, C., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-2782 · Cited by 549
Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus
Salpeter, S. R., Greyber, E., Pasternak, G. A., & Salpeter, E. E. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002967.pub3 · Cited by 447
Lee, C., & Longo, V. D. (2011) · Oncogene · doi:10.1038/onc.2011.91 · Cited by 313
Zhou, W., Mukherjee, P., Kiebish, M. A., Markis, W. T., Mantis, J. G., & Seyfried, T. N. (2007) · Nutrition & Metabolism · doi:10.1186/1743-7075-4-5 · Cited by 299
Batandier, C., Guigas, B., Detaille, D., El-Mir, M., Fontaine, E., Rigoulet, M., & Leverve, X. M. (2006) · Journal of Bioenergetics and Biomembranes · doi:10.1007/s10863-006-9003-8 · Cited by 279
In vitro metformin anti-neoplastic activity in epithelial ovarian cancer
Gotlieb, W. H., Saumet, J., Beauchamp, M.-C., Gu, J., Lau, S. K., Pollak, M., & Bruchim, I. (2008) · Gynecologic Oncology · doi:10.1016/j.ygyno.2008.04.008 · Cited by 270
Zhuang, Y., & Miskimins, W. K. (2008) · Journal of Molecular Signaling · doi:10.1186/1750-2187-3-18 · Cited by 251
Self-citationVazquez-Martin, A., Oliveras-Ferraros, C., & Menendez, J. A. (2009) · Cell Cycle · doi:10.4161/cc.8.1.7499 · Cited by 250 · cited 1×
“Many groups have demonstrated metformin’s action in vitro in a variety of cancer types [10–14].”
BackgroundWu, S., & Wei, Y. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2011.09.014 · Cited by 182
Saito, S., Furuno, A., Sakurai, J., Sakamoto, A., Park, H.-R., Shin‐ya, K., Tsuruo, T., & Tomida, A. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2689 · Cited by 164
Han, L., Ma, Q., Li, J., Liu, H., Li, W., Ma, G., Xu, Q., Zhou, S. Y., & Wu, E. (2011) · PLoS ONE · doi:10.1371/journal.pone.0027074 · Cited by 162
Metabolic management of brain cancer
Seyfried, T. N., Kiebish, M. A., Marsh, J., Shelton, L. M., Huysentruyt, L. C., & Mukherjee, P. (2010) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/j.bbabio.2010.08.009 · Cited by 148
Sandulache, V. C., Ow, T. J., Pickering, C. R., Frederick, M. J., Zhou, G., Fokt, I., Davis‐Malesevich, M., Priebe, W., & Myers, J. N. (2011) · Cancer · doi:10.1002/cncr.25868 · Cited by 143
Metformin is synthetically lethal with glucose withdrawal in cancer cells
Menéndez, J. A., Oliveras‐Ferraros, C., Cufí, S., Corominas-Faja, B., Joven, J., Martı́n-Castillo, B., & Vázquez‐Martín, A. (2012) · Cell Cycle · doi:10.4161/cc.20948 · Cited by 134
Central role of lactic acidosis in cancer cell resistance to glucose deprivation‐induced cell death
Wu, H., Ding, Z., Hu, D., Sun, F., Dai, C., Xie, J., & Hu, X. (2011) · The Journal of Pathology · doi:10.1002/path.3978 · Cited by 131
Zhuang, Y., & Miskimins, W. K. (2011) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-10-0343 · Cited by 113
Self-citationSinnett‐Smith, J. W., Kisfalvi, K., Kui, R. K., & Rozengurt, E. (2012) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2012.11.010 · Cited by 110
Caloric restriction reduces growth of mammary tumors and metastases
Lorenzo, M. S. D., Baljinnyam, E., Vatner, D. E., Abarzúa, P., Vatner, S. F., & Rabson, A. B. (2011) · Carcinogenesis · doi:10.1093/carcin/bgr107 · Cited by 107
Metformin as an energy restriction mimetic agent for breast cancer prevention
Thompson, H. J., Zhu, Z., Thompson, M., Jiang, W., & McGinley, J. N. (2011) · Journal of Carcinogenesis · doi:10.4103/1477-3163.83043 · Cited by 51
Bonini, M. G., & Gantner, B. N. (2013) · IUBMB Life · doi:10.1002/iub.1213 · Cited by 49
Carbon Source and Myc Expression Influence the Antiproliferative Actions of Metformin
Javeshghani, S., Zakikhani, M., Austin, S., Bazile, M., Blouin, M., Topisirović, I., St‐Pierre, J., & Pollak, M. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-2907 · Cited by 49
Lea, M. A., Chacko, J., Bolikal, S., Hong, J. Y., Chung, R., Ortega, A., & desBordes, C. (2011) · PubMed · Cited by 47
Andrade, B. M., Cazarin, J., Zancan, P., & de Carvalho, D. P. (2012) · Thyroid · doi:10.1089/thy.2012.0041 · Cited by 25
Smith, T., Zanda, M., & Fleming, I. N. (2013) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2013.05.006 · Cited by 25
Habibollahi, P., van den Berg, N. S., Kuruppu, D., Loda, M. F., & Mahmood, U. (2013) · Journal of Nuclear Medicine · doi:10.2967/jnumed.112.107011 · Cited by 24
Oleksyszyn, J. (2011) · Medical Hypotheses · doi:10.1016/j.mehy.2011.04.001 · Cited by 22
Rizkalla, S. W., Elgrably, F., Tchobroutsky, G., & Slama, G. (1986) · PubMed · Cited by 19
Matsuo, J., Tsukumo, Y., Saito, S., Tsukahara, S., Sakurai, J., Sato, S., Kondo, H., Ushijima, M., Matsuura, M., Watanabe, T., et al. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0871 · Cited by 17
Flagged first, then by citations
Research works printed but not linked: 1
- VC Sandulache, 2011, Glucose, not glutamine, is the dominant energy source required for proliferation and survival of head and neck squamous carcinoma cells, Cancer, 117, 2926, 10.1002/cncr.25868 · DOI
Cited by
Sorted by citations
Metabolites and the Tumour Microenvironment: From Cellular Mechanisms to Systemic Metabolism
Elia, I., & Haigis, M. C. (2021) · Nature Metabolism · doi:10.1038/s42255-020-00317-z · Cited by 651
Ketogenic diet in the treatment of cancer – Where do we stand?
Weber, D. D., Aminzadeh-Gohari, S., Tulipan, J., Catalano, L., Feichtinger, R. G., & Kofler, B. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.06.026 · Cited by 469
Elgendy, M., Cirò, M., Hosseini, A., Weiszmann, J., Mazzarella, L., Ferrari, E., Cazzoli, R., Curigliano, G., DeCensi, A., Bonanni, B., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.03.007 · Cited by 299
Targeting the Warburg effect for cancer treatment: Ketogenic diets for management of glioma
Poff, A. M., Koutnik, A. P., Egan, K. M., Sahebjam, S., D’Agostino, D. P., & Kumar, N. B. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.12.011 · Cited by 204
Klement, R. J. (2017) · Medical Oncology · doi:10.1007/s12032-017-0991-5 · Cited by 144
Metadata
- Authors
- Zhuang, Y., Chan, D. K., Haugrud, A. B., & Miskimins, W. K.
- Affiliations
- Sanford Research (US)
- University of South Dakota (US)
- Corresponding author
- Zhuang, Yongxian
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2014-09-25
- Volume
- 9
- Issue
- 9
- Pages
- e108444
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC4177919
- OpenAlex
- W2011662441
- Cited by
- 149
- References
- 42
- Citations by year
- 2026: 7 · 2025: 8 · 2024: 17 · 2023: 14 · 2022: 8 · 2021: 15 · 2020: 16 · 2019: 17 · 2018: 13 · 2017: 13 · 2016: 14 · 2015: 7
- FWCI
- 4.64
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Institutes of Health
- National Cancer Institute (R01CA180033)
- National Institute of General Medical Sciences (5P20GM10358, P20GM103548)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Keywords
- metformin, low glucose, tumor cell killing, breast cancer, ovarian cancer, glycolysis, AMPK, mTOR signaling, Akt phosphorylation, ATP depletion, fructose, galactose, ketogenic diet, tumor growth inhibition, metformin resistance
- MeSH terms
- Adenosine Triphosphate, Animals, Antineoplastic Agents, Blood Glucose, Cell Survival, Glucose, Glycolysis, Hypoglycemic Agents, Metformin, Neoplasms, Oxidative Phosphorylation, Phosphorylation, Drug Resistance, Neoplasm, Cell Line, Tumor, Proto-Oncogene Proteins c-akt, Mice, AMP-Activated Protein Kinases, Diet, Ketogenic, TOR Serine-Threonine Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
